Laetitia Lacroix
Overview
Explore the profile of Laetitia Lacroix including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
3993
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reot L, Adapen C, Cannou C, Nunez N, Lakoum S, Pimienta C, et al.
Sci Rep
. 2024 Sep;
14(1):21050.
PMID: 39251689
Seminal plasma (SP) is the main vector of C. trachomatis (CT) during heterosexual transmission from male to female. It has immunomodulatory properties and impacts the susceptibility to HIV-1 infection, but...
2.
Decroos A, Cheminant M, Bruneau J, Carras S, Parinet V, Pelletier L, et al.
Haematologica
. 2023 May;
108(10):2830-2836.
PMID: 37165836
No abstract available.
3.
Daugan M, Revel M, Lacroix L, Sautes-Fridman C, Fridman W, Roumenina L
Methods Mol Biol
. 2021 Apr;
2227:191-203.
PMID: 33847943
Tumors contain a complement rich microenvironment in which all cell types (e.g., tumor cells and stromal cells) are able to produce different proteins. We developed immunohistochemistry (IHC) assays allowing to...
4.
Meylan M, Petitprez F, Lacroix L, Di Tommaso L, Roncalli M, Bougouin A, et al.
Clin Cancer Res
. 2020 Apr;
26(16):4381-4389.
PMID: 32269054
Purpose: The impact of tertiary lymphoid structures (TLS) in hepatocellular carcinoma (HCC) progression is being extensively investigated. However, their presence during the early steps of human liver carcinogenesis remains unknown....
5.
Petitprez F, De Reynies A, Keung E, Chen T, Sun C, Calderaro J, et al.
Nature
. 2020 Jan;
577(7791):556-560.
PMID: 31942077
Soft-tissue sarcomas represent a heterogeneous group of cancer, with more than 50 histological subtypes. The clinical presentation of patients with different subtypes is often atypical, and responses to therapies such...
6.
Laurent C, Nicolae A, Laurent C, Le Bras F, Haioun C, Fataccioli V, et al.
Blood
. 2019 Nov;
135(5):360-370.
PMID: 31774495
The oncogenic events involved in breast implant-associated anaplastic large cell lymphoma (BI-ALCL) remain elusive. To clarify this point, we have characterized the genomic landscape of 34 BI-ALCLs (15 tumor and...
7.
Di Giacomo A, Covre A, Finotello F, Rieder D, Danielli R, Sigalotti L, et al.
Clin Cancer Res
. 2019 Sep;
25(24):7351-7362.
PMID: 31530631
Purpose: The immunomodulatory activity of DNA hypomethylating agents (DHAs) suggests they may improve the effectiveness of cancer immunotherapies. The phase Ib NIBIT-M4 trial tested this hypothesis using the next-generation DHA...
8.
Roumenina L, Daugan M, Noe R, Petitprez F, Vano Y, Sanchez-Salas R, et al.
Cancer Immunol Res
. 2019 Jun;
7(7):1091-1105.
PMID: 31164356
Clear-cell renal cell carcinoma (ccRCC) possesses an unmet medical need, particularly at the metastatic stage, when surgery is ineffective. Complement is a key factor in tissue inflammation, favoring cancer progression...
9.
Ijsselsteijn M, Petitprez F, Lacroix L, Ruano D, van der Breggen R, Julie C, et al.
Br J Cancer
. 2019 Mar;
120(8):815-818.
PMID: 30862951
In colorectal cancer (CRC), T-cell checkpoint blockade is only effective in patients diagnosed with mismatch repair-deficient (MMR-d) cancers. However, defects in Human Leukocyte Antigen (HLA) class I expression were reported...
10.
Petitprez F, Sun C, Lacroix L, Sautes-Fridman C, De Reynies A, Fridman W
Front Oncol
. 2018 Oct;
8:390.
PMID: 30319963
Tumors are formed by aggregates of cells of various origins including malignant, stromal and immune cells. The number of therapies targeting the microenvironment is increasing as the tumor microenvironment is...